Comparison 5. Sensitivity analysis (excluding studies with an active comparator).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 All‐cause mortality – at 28 to 30 days, or in‐hospital	9	3024	Risk Ratio (M‐H, Random, 95% CI)	0.83 [0.40, 1.75]
5.1.1 Favipiravir versus standard care/placebo	9	3024	Risk Ratio (M‐H, Random, 95% CI)	0.83 [0.40, 1.75]
5.2 Progression to invasive mechanical ventilation	7	1010	Risk Ratio (M‐H, Random, 95% CI)	0.81 [0.62, 1.06]
5.2.1 Favipiravir versus standard care/placebo	7	1010	Risk Ratio (M‐H, Random, 95% CI)	0.81 [0.62, 1.06]
5.3 Need for critical or intensive care (any reason)	3	774	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.48, 1.91]
5.3.1 Favipiravir versus standard care/placebo	3	774	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.48, 1.91]
5.4 All adverse events	17	4463	Risk Ratio (M‐H, Random, 95% CI)	1.27 [1.03, 1.56]
5.4.1 Favipiravir versus standard care/placebo	17	4463	Risk Ratio (M‐H, Random, 95% CI)	1.27 [1.03, 1.56]
5.5 Hyperuricaemia	9	2236	Risk Ratio (M‐H, Random, 95% CI)	5.04 [2.63, 9.64]
5.5.1 Favipiravir versus standard care/placebo	9	2236	Risk Ratio (M‐H, Random, 95% CI)	5.04 [2.63, 9.64]